PMID- 18775433
OWN - NLM
STAT- MEDLINE
DCOM- 20081202
LR  - 20171116
IS  - 0022-1759 (Print)
IS  - 0022-1759 (Linking)
VI  - 339
IP  - 1
DP  - 2008 Nov 30
TI  - Detection of humoral response in patients with glioblastoma receiving 
      EGFRvIII-KLH vaccines.
PG  - 74-81
LID - 10.1016/j.jim.2008.08.004 [doi]
AB  - The epidermal growth factor receptor variant III (EGFRvIII) is a consistent 
      tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) 
      and other neoplasms. As such it represents a truly tumor-specific target for 
      antitumor immunotherapy. Although endogenous humoral responses to EGFRvIII have 
      been reported in patients with EGFRvIII-expressing breast cancer, it is not known 
      whether de novo responses can be generated or endogenous responses enhanced with 
      an EGFRvIII-specific vaccine. To assess this in clinical trials, we have 
      developed and validated an immunoassay to measure and isolate anti-EGFRvIII and 
      anti-KLH antibodies from the serum of patients vaccinated with an 
      EGFRvIII-specific peptide (PEPvIII) conjugated to keyhole limpet hemocyanin 
      (KLH). Using magnetic beads with immobilized antigen we captured and detected 
      anti-EGFRvIII and anti-KLH antibodies in serum from patients before and after 
      vaccinations. Using this assay, we found that significant levels of antibody for 
      tumor-specific antigen EGFRvIII (>4 microg/mL) and KLH could be induced after 
      vaccination with PEPvIII-KLH.
FAU - Schmittling, Robert J
AU  - Schmittling RJ
AD  - Division of Neurosurgery, Department of Surgery, Duke University Medical Center, 
      Durham, NC 27710, USA. schmi028@mc.duke.edu
FAU - Archer, Gary E
AU  - Archer GE
FAU - Mitchell, Duane A
AU  - Mitchell DA
FAU - Heimberger, Amy
AU  - Heimberger A
FAU - Pegram, Charles
AU  - Pegram C
FAU - Herndon, James E 2nd
AU  - Herndon JE 2nd
FAU - Friedman, Henry S
AU  - Friedman HS
FAU - Bigner, Darell D
AU  - Bigner DD
FAU - Sampson, John H
AU  - Sampson JH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20080904
PL  - Netherlands
TA  - J Immunol Methods
JT  - Journal of immunological methods
JID - 1305440
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 9013-72-3 (Hemocyanins)
RN  - EC 2.7.10.1 (FGFR3 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3)
RN  - FV4Y0JO2CX (keyhole-limpet hemocyanin)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Antibodies, Neoplasm/*blood/immunology
MH  - *Antibody Formation/drug effects/immunology
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Female
MH  - Glioblastoma/*blood/immunology/therapy
MH  - Hemocyanins/immunology/*therapeutic use
MH  - Humans
MH  - Male
MH  - Receptor, Fibroblast Growth Factor, Type 3/immunology/*therapeutic use
MH  - Vaccination/methods
EDAT- 2008/09/09 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/09/09 09:00
PHST- 2008/06/25 00:00 [received]
PHST- 2008/08/08 00:00 [revised]
PHST- 2008/08/12 00:00 [accepted]
PHST- 2008/09/09 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/09/09 09:00 [entrez]
AID - S0022-1759(08)00254-8 [pii]
AID - 10.1016/j.jim.2008.08.004 [doi]
PST - ppublish
SO  - J Immunol Methods. 2008 Nov 30;339(1):74-81. doi: 10.1016/j.jim.2008.08.004. Epub 
      2008 Sep 4.